Nasdaq

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
The Motley Fool

Is Recursion Pharmaceuticals a Millionaire Maker?

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX 2.48%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...
GEN

Recursion’s Fast-Track Road to Therapeutics Using AI-Based Maps of Biology

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
Nasdaq

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
The Motley Fool

Recursion Pharmaceuticals Is Going Big on AI. Here's Why It Could Be Worth Buying

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and development (R&D) costs and timelines. To accomplish that, it employs a ...